Hospital
Honorhealth
Honorhealth was paid $65.78M by Medicaid between Jan 2018 and Dec 2024, across 360 billing codes. Its largest line is 99285, emergency room visit (most serious) — 24% of everything it billed.
33Billing provider infoHONORHEALTH
PHOENIX, AZ 85027
PHOENIX, AZ 85027
33aNPI1528169125assigned 09/26/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$65.78M
24GClaims1,911,271
24DCodes billed360
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arizona
Rank by total paid#6 of 78
Median peer was paid$12.21M
This provider vs. median5.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 315,524 | $10.50M | |
| 2019 | 306,860 | $10.99M | |
| 2020 | 255,939 | $9.11M | |
| 2021 | 277,056 | $8.97M | |
| 2022 | 279,842 | $9.14M | |
| 2023 | 280,183 | $9.47M | |
| 2024incomplete | 195,867 | $7.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 24% | 36,343 | 32,399 | $15.96M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 41,561 | 39,034 | $10.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.4% | 35,881 | 33,054 | $6.18M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.2% | 18,088 | 16,450 | $4.71M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.7% | 33,726 | 31,778 | $3.77M |
| 72125 | Computed tomography, cervical spine; without contrast material | 4.1% | 7,448 | 6,808 | $2.71M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.1% | 4,677 | 4,408 | $2.67M |
| G0378 | Hospital observation service, per hour | 4.0% | 36,718 | 14,468 | $2.65M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.8% | 7,150 | 6,513 | $1.85M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.6% | 24,904 | 8,250 | $1.69M |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 33,712 | 25,362 | $1.34M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 16,662 | 14,987 | $1.24M |
348 more codes
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.5% | 2,826 | $986K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.2% | 471 | $794K |
| 70498 | 1.0% | 1,896 | $680K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 22,030 | $603K |
| 74174 | <1% | 750 | $587K | |
| 72131 | <1% | 1,306 | $558K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 6,684 | $523K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,181 | $489K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,336 | $409K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 9,748 | $316K |
| 76801 | <1% | 1,512 | $297K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,925 | $236K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 769 | $233K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,779 | $231K |
| 76641 | <1% | 2,918 | $219K | |
| 93798 | <1% | 2,323 | $181K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,210 | $166K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,470 | $165K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 930 | $159K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,693 | $149K |
| 77066 | Tomosynthesis, mammo | <1% | 2,001 | $143K |
| 47562 | <1% | 44 | $137K | |
| 71250 | <1% | 1,534 | $118K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 483 | $112K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,069 | $97K |
| 93976 | <1% | 1,198 | $96K | |
| 70496 | <1% | 1,704 | $93K | |
| 70491 | <1% | 178 | $88K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,288 | $80K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,449 | $80K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 9,678 | $65K |
| 76830 | Ultrasound, transvaginal | <1% | 1,271 | $62K |
| 97161 | <1% | 7,196 | $62K | |
| C1781 | Mesh (implantable) | <1% | 275 | $56K |
| 93458 | <1% | 42 | $53K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,592 | $46K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,599 | $43K |
| 77080 | <1% | 1,144 | $43K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,502 | $38K |
| 70487 | <1% | 63 | $33K | |
| 93970 | <1% | 1,957 | $32K | |
| 10060 | <1% | 199 | $32K | |
| 97165 | <1% | 3,715 | $30K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,797 | $29K |
| 72141 | <1% | 337 | $26K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,508 | $23K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 39,776 | $22K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 43,529 | $21K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 55 | $19K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,750 | $19K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 296 | $19K |
| 73564 | <1% | 459 | $17K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 28 | $17K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,746 | $16K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 42,696 | $16K |
| 96376 | <1% | 19,098 | $15K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,809 | $14K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 30 | $14K |
| 80053 | Comprehensive metabolic panel | <1% | 67,980 | $11K |
| 76642 | <1% | 509 | $10K | |
| 72128 | <1% | 59 | $10K | |
| 93971 | <1% | 2,665 | $8K | |
| 71045 | Radiologic examination, chest; single view | <1% | 33,575 | $7K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 23 | $7K |
| C1769 | Guide wire | <1% | 3,094 | $7K |
| 73630 | <1% | 3,009 | $6K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32,902 | $6K |
| 49083 | <1% | 17 | $6K | |
| 74178 | <1% | 16 | $6K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,276 | $5K |
| 88341 | <1% | 114 | $5K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 78,572 | $5K |
| 12001 | <1% | 1,356 | $5K | |
| 43450 | <1% | 179 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 11,360 | $4K |
| 73502 | <1% | 988 | $4K | |
| 73610 | <1% | 2,502 | $4K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 4,409 | $4K |
| 76770 | <1% | 152 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 10,651 | $4K |
| 70486 | <1% | 2,134 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,686 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,163 | $3K |
| 85610 | <1% | 27,400 | $3K | |
| 97116 | <1% | 4,052 | $3K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 48 | $3K |
| 70544 | <1% | 43 | $3K | |
| 84484 | <1% | 35,489 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 22,557 | $2K |
| 77049 | <1% | 14 | $2K | |
| 73700 | <1% | 95 | $2K | |
| 81001 | <1% | 49,095 | $2K | |
| 73130 | <1% | 2,578 | $2K | |
| 80061 | Lipid panel | <1% | 3,559 | $2K |
| 72100 | <1% | 705 | $2K | |
| 73030 | <1% | 2,594 | $2K | |
| 12011 | <1% | 951 | $2K | |
| 83690 | <1% | 28,265 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,599 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,016 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 41,160 | $1K |
| 84703 | <1% | 18,773 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,041 | $1K |
| 87040 | <1% | 10,809 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,995 | $1K |
| 83880 | <1% | 8,147 | $1K | |
| 80306 | <1% | 12,854 | $1K | |
| 74018 | <1% | 2,236 | $1K | |
| 87631 | <1% | 967 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 29,559 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23,014 | $1K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 16,948 | $962.78 |
| 86850 | <1% | 4,787 | $913.90 | |
| 82803 | <1% | 1,553 | $879.99 | |
| 83735 | <1% | 27,068 | $839.31 | |
| 73110 | <1% | 1,769 | $830.74 | |
| 82962 | <1% | 32,039 | $828.36 | |
| 73562 | <1% | 2,616 | $811.38 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,627 | $805.17 |
| 82248 | <1% | 18,131 | $802.22 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 127 | $783.25 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 21,827 | $751.42 |
| 81025 | <1% | 9,663 | $718.44 | |
| 87400 | <1% | 5,002 | $692.18 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,358 | $679.40 |
| 73090 | <1% | 1,460 | $654.88 | |
| 83605 | <1% | 12,154 | $653.13 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 300 | $637.05 |
| 85730 | <1% | 14,389 | $635.35 | |
| 73590 | <1% | 1,597 | $609.94 | |
| 87186 | <1% | 5,375 | $603.46 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 7,450 | $599.22 |
| 84702 | <1% | 3,162 | $585.99 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,911 | $575.35 |
| 85379 | <1% | 9,595 | $551.42 | |
| 76870 | <1% | 175 | $531.08 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23,362 | $500.73 |
| 73140 | <1% | 610 | $482.00 | |
| 87077 | <1% | 6,765 | $477.46 | |
| 72040 | <1% | 96 | $430.34 | |
| 87070 | <1% | 2,722 | $430.10 | |
| 74019 | <1% | 1,304 | $419.30 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,014 | $398.74 |
| 90715 | <1% | 3,181 | $394.97 | |
| 94760 | <1% | 20,511 | $387.76 | |
| 80076 | <1% | 570 | $374.19 | |
| 87510 | <1% | 1,538 | $364.63 | |
| 87480 | <1% | 1,538 | $349.55 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 458 | $339.40 |
| 86900 | <1% | 5,863 | $327.80 | |
| 87081 | <1% | 2,494 | $286.55 | |
| 85027 | <1% | 23,848 | $278.11 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $274.40 |
| 87660 | <1% | 1,538 | $264.02 | |
| 73080 | <1% | 870 | $263.68 | |
| 93017 | <1% | 475 | $259.98 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 32,855 | $248.15 |
| 82550 | <1% | 6,695 | $246.92 | |
| 92523 | <1% | 351 | $237.19 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,816 | $219.52 |
| J3490 | Unclassified drugs | <1% | 3,479 | $217.08 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,719 | $213.16 |
| 84132 | <1% | 4,899 | $210.56 | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 20 | $191.77 |
| 96367 | <1% | 2,697 | $181.99 | |
| 82728 | <1% | 856 | $179.52 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14,201 | $176.71 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,349 | $171.55 |
| 80050 | General health panel | <1% | 303 | $168.59 |
| 86901 | <1% | 6,140 | $163.01 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 3,398 | $160.14 |
| 97162 | <1% | 41 | $159.79 | |
| 80320 | <1% | 10,286 | $157.15 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,679 | $153.51 |
| 87205 | <1% | 3,528 | $147.33 | |
| 72170 | <1% | 389 | $147.00 | |
| 84100 | <1% | 9,680 | $142.73 | |
| 82150 | <1% | 2,913 | $135.30 | |
| 82565 | <1% | 624 | $135.00 | |
| 84520 | <1% | 428 | $133.00 | |
| 29125 | <1% | 288 | $131.69 | |
| 80329 | <1% | 4,712 | $130.93 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,694 | $127.31 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 10,264 | $124.58 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,096 | $115.82 |
| 0352U | <1% | 331 | $114.10 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,558 | $112.05 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 24,166 | $111.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,636 | $104.68 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,769 | $103.87 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 5,099 | $98.64 |
| 74022 | <1% | 206 | $82.16 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 5,938 | $81.25 |
| 84145 | <1% | 1,834 | $75.03 | |
| 82140 | <1% | 1,578 | $65.42 | |
| 73560 | <1% | 59 | $60.54 | |
| 86141 | <1% | 1,372 | $56.25 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 9,274 | $54.80 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 4,205 | $49.34 |
| 83050 | <1% | 545 | $48.90 | |
| 99152 | <1% | 2,048 | $46.65 | |
| 86635 | <1% | 560 | $44.64 | |
| 82330 | <1% | 963 | $43.51 | |
| 80074 | <1% | 545 | $42.71 | |
| 87075 | <1% | 1,269 | $41.96 | |
| 83540 | <1% | 361 | $41.91 | |
| 82010 | <1% | 549 | $40.83 | |
| 83550 | <1% | 340 | $38.69 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,566 | $33.42 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,858 | $32.98 |
| 71101 | <1% | 114 | $32.32 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 3,351 | $29.27 |
| 82375 | <1% | 548 | $28.06 | |
| 82553 | <1% | 1,168 | $27.25 | |
| 85652 | <1% | 2,648 | $27.17 | |
| J2704 | Injection, propofol, 10 mg | <1% | 18,428 | $24.30 |
| 82810 | <1% | 573 | $23.40 | |
| 88304 | <1% | 1,497 | $21.24 | |
| 84439 | <1% | 1,353 | $20.68 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 241 | $20.44 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,721 | $19.78 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,261 | $18.58 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 925 | $18.16 |
| 85007 | <1% | 2,882 | $17.28 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 494 | $16.40 |
| 87147 | <1% | 1,702 | $15.45 | |
| 82947 | <1% | 1,347 | $15.22 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 264 | $14.71 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 515 | $14.37 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,545 | $14.19 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,339 | $12.57 |
| 84295 | <1% | 935 | $11.69 | |
| 87807 | <1% | 581 | $11.48 | |
| 85014 | <1% | 1,983 | $11.04 | |
| 81003 | <1% | 718 | $10.98 | |
| 86140 | <1% | 937 | $10.35 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 661 | $9.28 |
| 82435 | <1% | 866 | $9.07 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,279 | $6.10 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 743 | $5.60 |
| 94762 | <1% | 870 | $5.16 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 148 | $4.54 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 2,714 | $3.62 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 2,716 | $3.00 |
| J1815 | Injection, insulin, per 5 units | <1% | 2,013 | $2.34 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 6,441 | $1.14 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 245 | $0.94 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,389 | $0.11 |
| 77062 | 0% | 1,827 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 85 | $0.00 |
| 82272 | 0% | 224 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 687 | $0.00 |
| 82374 | 0% | 167 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 441 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 4,431 | $0.00 |
| C1729 | Catheter, drainage | 0% | 189 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 226 | $0.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 4,053 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,775 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 574 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 1,084 | $0.00 |
| 87102 | 0% | 35 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 564 | $0.00 |
| 0042T | 0% | 143 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 439 | $0.00 |
| 77061 | 0% | 1,302 | $0.00 | |
| 82570 | 0% | 16 | $0.00 | |
| 82310 | 0% | 505 | $0.00 | |
| 85347 | 0% | 92 | $0.00 | |
| 92610 | 0% | 184 | $0.00 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 38 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 37 | $0.00 |
| 69210 | 0% | 14 | $0.00 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 21 | $0.00 |
| 89051 | 0% | 65 | $0.00 | |
| 76937 | 0% | 26 | $0.00 | |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 127 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 18 | $0.00 |
| 29105 | 0% | 37 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 176 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 37 | $0.00 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 82 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 18 | $0.00 |
| P9021 | Red blood cells, each unit | 0% | 14 | $0.00 |
| L8613 | Ossicula implant | 0% | 30 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 91 | $0.00 |
| 87076 | 0% | 15 | $0.00 | |
| 76376 | 0% | 13 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 34 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 13 | $0.00 |
| 86923 | 0% | 16 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 22 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 18 | $0.00 |
| 80202 | 0% | 20 | $0.00 | |
| 29515 | 0% | 12 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 26,647 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 313 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 858 | $0.00 |
| 12002 | 0% | 422 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 217 | $0.00 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 676 | $0.00 |
| 88342 | 0% | 3,598 | $0.00 | |
| 80069 | 0% | 597 | $0.00 | |
| 86308 | 0% | 119 | $0.00 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 4,759 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 174 | $0.00 |
| 88307 | 0% | 702 | $0.00 | |
| 82746 | 0% | 50 | $0.00 | |
| 85018 | 0% | 422 | $0.00 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 32 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 852 | $0.00 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 91 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 158 | $0.00 |
| 83615 | 0% | 168 | $0.00 | |
| 82607 | 0% | 244 | $0.00 | |
| 84157 | 0% | 132 | $0.00 | |
| 76377 | 0% | 242 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 206 | $0.00 |
| 64488 | 0% | 119 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 427 | $0.00 |
| 36416 | 0% | 13 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 323 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 416 | $0.00 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 25 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 430 | $0.00 |
| J0456 | Injection, azithromycin, 500 mg | 0% | 266 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 31 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 49 | $0.00 |
| 96368 | 0% | 32 | $0.00 | |
| 73060 | 0% | 91 | $0.00 | |
| 93797 | 0% | 24 | $0.00 | |
| 73552 | 0% | 68 | $0.00 | |
| 87493 | 0% | 43 | $0.00 | |
| 77001 | 0% | 148 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 20 | $0.00 |
| 94644 | 0% | 12 | $0.00 | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 28 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 34 | $0.00 |
| 82270 | 0% | 39 | $0.00 | |
| 70547 | 0% | 16 | $0.00 | |
| 36410 | 0% | 33 | $0.00 | |
| 86885 | 0% | 12 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 20 | $0.00 |
| 84300 | 0% | 15 | $0.00 | |
| 88311 | 0% | 13 | $0.00 | |
| 86592 | 0% | 12 | $0.00 | |
| 90686 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHENDRIX, JENIFER (SENIOR NETWORK DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Honorhealth | Phoenix, AZ | $107.15M |
| Honorhealth | Scottsdale, AZ | $47.05M |
| Honorhealth | Scottsdale, AZ | $23.83M |
| Honorhealth | Phoenix, AZ | $7.97M |
| Honorhealth | Scottsdale, AZ | $7.44M |
| Honorhealth | Surprise, AZ | $3.33M |
| Honorhealth | Scottsdale, AZ | $232K |
| Honorhealth | Scottsdale, AZ | $13K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.